Gland B2B Business Model and Growth Strategy slide image

Gland B2B Business Model and Growth Strategy

Generic Injectables: Growth Opportunity US$131bn Market with Multiple Growth Levers Driven by LoEs, Opportunity from Shortages and Ease of Use Sizeable Injectable Market ... Injectable is a >US$400bn market Growing Faster than Broader Market with Robust Growth in Generics Injectable recorded CAGR of 10.1% vs broader market at 5.8% Global Injectable Market Global Pharma - Drug Delivery Mix 14-19 Key injectable markets like US, Europe and India demonstrated double digit/high single digit growth Geographic Mix- Generic Injectable 14-19 Global Pharma 826 1,096 CAGR CAGR Market Size (US$bn) 131 (US$bn) 1,096 (US$bn) 6% 8% 32% 39% 826 174 3% 89 c.10% CAGR 432 147 1 432 267 10% 30 267 14 412 490 4% 18 2224 34 9% 20 3% 29 6% 10% 46 25 13% 2014 2019 2014 2014 2019 Oral Solids ■Injectable Others ■North America 2019 Europe China India LOE Offering Significant Opportunity Significant increase in value of injectable brand sales scheduled to lose exclusivity Loss of Exclusivity - Injectables (US$bn) 33 61 2014-19 2019-24 Demand Driven by Drug Shortages c.40-60% of US drug shortages are in injectables Accessibility and Ease of Use Convenience and benefits of New Drug Delivery Systems driving growth across delivery formats Global Injectable Market 14-19 (US$bn) CAGR (% Injectables Share) 45% 45% 63% 58% 55% 39% 432 10% 66 10% 267 97 (#) 5% 42 84 102 57 61 101 77 131 78 15% 67 83 97 64 85 102 65 138 11% 81 2014 2015 2016 2017 2018 2019 2014 2019 20 20 ■Injectables ■Non-Injectables Source: IQVIA Report. Note: MAT September 2014-2019. (1) Generic Injectable market share as a percentage of overall injectable market in the respective country. Infusions Pre-filled Syringes Vials Others GLAND
View entire presentation